Amsterdam Academic Ventures company Amplio Pharma announced encouraging early results for a new rheumatoid arthritis treatment called NovoBioJect. In a small study with 12 patients, the treatment helped to generate more of the active form of methotrexate, the most widely used first medicine for this disease, inside the immune cells that drive inflammation. The company reports no side effects other than mild reactions at the injection site.